Buy Exelixis (EXEL) stock [Updated daily] |

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Exelixis stock | $22.37

Own Exelixis stock in just a few minutes.

Exelixis, Inc (EXEL) is a leading biotechnology business based in the US. It opened the day at USD$22.17 after a previous close of USD$22.21. During the day the price has varied from a low of USD$21.99 to a high of USD$22.44. The latest price was USD$22.37 (25 minute delay). Exelixis is listed on the NASDAQ and employs 773 staff. All prices are listed in US Dollars.

How to buy shares in Exelixis

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Exelixis. Find the stock by name or ticker symbol: EXEL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Exelixis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$22.37, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Exelixis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Exelixis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Exelixis's share price?

Since the stock market crash in March caused by coronavirus, Exelixis's share price has had significant positive movement.

Its last close price was USD$22.37, which is 5.72% up on its pre-crash value of USD$21.09 and 63.64% up on the lowest point reached during the March crash when the shares fell as low as USD$13.67.

If you had bought USD$1,000 worth of Exelixis shares at the start of February 2020, those shares would have been worth USD$877.60 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,279.79.

Exelixis share price

Use our graph to track the performance of EXEL stocks over time.

Exelixis shares at a glance

Information last updated 2021-03-11.
Previous closeUSD$22.21
Change USD$0.16
Change % 0.7204%
Volume 272,880
Information last updated 2021-04-08.
52-week rangeUSD$17.54 - USD$27.8
50-day moving average USD$22.5663
200-day moving average USD$21.9388
Wall St. target priceUSD$31.36
PE ratio 66.7429
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.35

Buy Exelixis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Exelixis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Exelixis under- or over-valued?

Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exelixis's P/E ratio

Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Exelixis shares trade at around 67x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Exelixis's PEG ratio

Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1967. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Exelixis's EBITDA

Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$121.9 million.

The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.

Exelixis financials

Revenue TTM USD$987.5 million
Operating margin TTM 11.42%
Gross profit TTM USD$954 million
Return on assets TTM 3.5%
Return on equity TTM 6.27%
Profit margin 11.32%
Book value $6.03
Market capitalisation USD$7.3 billion

TTM: trailing 12 months

Shorting Exelixis shares

There are currently 13.3 million Exelixis shares held short by investors – that's known as Exelixis's "short interest". This figure is 5.2% up from 12.6 million last month.

There are a few different ways that this level of interest in shorting Exelixis shares can be evaluated.

Exelixis's "short interest ratio" (SIR)

Exelixis's "short interest ratio" (SIR) is the quantity of Exelixis shares currently shorted divided by the average quantity of Exelixis shares traded daily (recently around 1.9 million). Exelixis's SIR currently stands at 7.17. In other words for every 100,000 Exelixis shares traded daily on the market, roughly 7170 shares are currently held short.

However Exelixis's short interest can also be evaluated against the total number of Exelixis shares, or, against the total number of tradable Exelixis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exelixis's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Exelixis shares in existence, roughly 40 shares are currently held short) or 0.0481% of the tradable shares (for every 100,000 tradable Exelixis shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Exelixis.

Find out more about how you can short Exelixis stock.

Exelixis share dividends

We're not expecting Exelixis to pay a dividend over the next 12 months.

Exelixis share price volatility

Over the last 12 months, Exelixis's shares have ranged in value from as little as $17.54 up to $27.8. A popular way to gauge a stock's volatility is its "beta".

EXEL.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 1.0452. This would suggest that Exelixis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Exelixis overview

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site